文献速递神经肿瘤

ABCG2与XIAP在胶质母细胞瘤中的表达及功能

Expression and function of ABCG2 and XIAP in glioblastomas.
PubMed 文献 · J Neurooncol · 2017-04-21

研究通过免疫组化检测50例胶质母细胞瘤样本中8种蛋白表达并分析生存,发现ABCG2或XIAP高表达者生存更差,调整后风险比分别为2.35和2.65;体外实验显示ABCG2抑制剂Ko143和fumitremorgin可显著减少患者来源肿瘤球自我更新。

要点

  • ABCG2或XIAP蛋白高表达的胶质母细胞瘤患者生存更差,调整后风险比分别为2.35和2.65。
  • ABCG2抑制剂Ko143和fumitremorgin可显著减少患者来源胶质母细胞瘤肿瘤球的自我更新。
  • ABCG2和XIAP或可作为患者生存的指标,抑制ABCG2可能是胶质母细胞瘤有前景的治疗策略。

核心结论

  • ABCG2和XIAP蛋白高表达与胶质母细胞瘤患者更差生存相关,抑制ABCG2可能是胶质母细胞瘤有前景的治疗策略。

研究设计与样本

  • 免疫组化检测50例胶质母细胞瘤样本中8种与治疗抵抗和癌细胞存活相关蛋白的表达并分析患者生存。
  • 体外用小分子抑制剂处理患者来源的胶质母细胞瘤肿瘤球。

主要发现

  • ABCG2或XIAP蛋白高表达的胶质母细胞瘤患者生存差于低表达者,调整后风险比ABCG2为2.35、XIAP为2.65。
  • ABCG2抑制剂Ko143和fumitremorgin显著减少患者来源胶质母细胞瘤肿瘤球的自我更新。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite multimodal treatment that includes surgery, radiation and chemotherapy, virtually all glioblastomas (GBM) recur, indicating that these interventions are insufficient to eradicate all malignant cells. To identify potential new therapeutic targets in GBMs, we examined the expression and function of proteins that are associated with therapy resistance and cancer cell survival. We measured the expression of eight such proteins in 50 GBM samples by immunohistochemistry and analyzed patient survival. We report that GBM patients with high expression of ABCG2 (also called BCRP) or XIAP at the protein level had worse survival than those with low expression. The adjusted hazard ratio for ABCG2 was 2.35 and for XIAP was 2.65. Since glioma stem cells (GSCs) have been shown to be more resistant than bulk tumor cells to anti-cancer therapies and to express high levels of these proteins, we also sought to determine if ABCG2 and XIAP have functional roles in GSCs. We used small molecule inhibitors to treat patient-derived GBM tumorspheres in vitro and observed that inhibitors of ABCG2, Ko143 and fumitremorgin, significantly reduced self-renewal. These results suggest that ABCG2 and XIAP proteins may be useful indicators of patient survival and that inhibition of ABCG2 may be a promising therapeutic strategy in GBMs.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Emery IF, Gopalan A, Wood S, et al. Expression and function of ABCG2 and XIAP in glioblastomas. J Neurooncol. 2017. PMID: 28432589. doi:10.1007/s11060-017-2422-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。